Keybank National Association OH Sells 571,857 Shares of Kenvue Inc. $KVUE

Keybank National Association OH trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 35.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,055,555 shares of the company’s stock after selling 571,857 shares during the quarter. Keybank National Association OH’s holdings in Kenvue were worth $18,198,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Cornerstone Wealth Group LLC lifted its position in shares of Kenvue by 5.9% in the first quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock worth $187,000 after buying an additional 606 shares during the last quarter. Physician Wealth Advisors Inc. boosted its stake in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares in the last quarter. Mill Creek Capital Advisors LLC increased its holdings in shares of Kenvue by 0.6% during the 4th quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock valued at $2,143,000 after acquiring an additional 701 shares during the last quarter. B & T Capital Management DBA Alpha Capital Management increased its holdings in shares of Kenvue by 0.3% during the 4th quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock valued at $4,048,000 after acquiring an additional 712 shares during the last quarter. Finally, Philip James Wealth Mangement LLC raised its stake in shares of Kenvue by 5.5% in the 4th quarter. Philip James Wealth Mangement LLC now owns 13,888 shares of the company’s stock valued at $240,000 after acquiring an additional 726 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Down 0.1%

KVUE opened at $19.81 on Friday. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $22.87. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $38.03 billion, a price-to-earnings ratio of 23.30, a P/E/G ratio of 1.50 and a beta of 0.47. The business has a 50 day moving average of $17.86 and a 200-day moving average of $17.71.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same quarter in the previous year, the firm posted $0.24 earnings per share. Kenvue’s revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.2%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insider Transactions at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.59% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on KVUE. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. UBS Group dropped their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 7th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Finally, Argus raised shares of Kenvue to a “hold” rating in a report on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.